Navigation Links
Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
Date:4/1/2009

ADDISON, Texas, April 1 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data on the physical properties of Altrazeal(TM) Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "Since the launch of Altrazeal(TM) in June 2008, we have accumulated extensive clinical experience across all wound types. The presentation of this data in a formal forum is a reflection of the execution of an important part of our 2009 business strategy."

Dr. Brock Liden, DPM of the Berger Health Care Center in Circleville, Iowa, will discuss at one podium presentation a talk titled "Treatment methods and experience with a novel aggregating powder dressing." In this presentation, Dr. Liden will detail his experiences and best clinical practice using Altrazeal(TM), application techniques, and what to expect when applying and treating wounds with the dressing.

In addition, clinical evidence using Altrazeal(TM) in treatment of diabetic foot ulcers, surgical wounds, and difficult to treat wounds such as those on sickle cell patients or patients afflicted with lymphangioma or pyoderma will be presented. A total of five posters detailing clinical evidence of Altrazeal(TM) will be displayed including one that shows the successful use of Altrazeal(TM) under contact casts in the treatment of diabetic foot ulcers. Commenting on the product, Dr. Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, and author of three of the posters stated, "Altrazeal(TM) is proving to be a very versatile dress
'/>"/>

SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
2. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
3. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
4. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
5. By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
6. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
7. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
8. Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
9. Task Force Recommends Screening Adolescents for Clinical Depression
10. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
11. Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... December 22, 2014 BellasDress.com offers a ... for women. Today, it announces its BellasDress Christmas ... at its online store. , BellasDress is a famous ... to its fans through a series of promotions. The ... every customer. , “We are proud of offering ...
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas joy ... helping people get their health back. Mission for area ... those persons in Muskegon County who are unable to find ... life. Dr. Michael Rykse wanted to do a Toy Drive ... he knew he found that when he heard what MAP ...
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... , MONDAY, Aug. 3 (HealthDay News) -- Common variants of ... increased risk of pancreatic cancer, according to U.S. researchers. , ... patients and more than 4,500 people without the disease. This ... that produce the blood types A, B or AB are ...
... enough , MONDAY, Aug. 3 (HealthDay News) -- Most American ... associated with an increased incidence of risk factors for cardiovascular ... find. , Simultaneous publication of both papers in the Aug. ... lead authors of the reports said. Both used U.S. data ...
... study published in the August issue of The Journal ... is an important tool for depicting the extent of neuroblastoma ... of the disease. Neuroblastoma accounts for six to ten percent ... percent of cancer deaths in children. Accurately identifying where in ...
... , BOSTON, Aug. 3 AMICAS, Inc. (Nasdaq: ... solutions, today announced a new contract with The Hospital of Central ... Connecticut to achieve its reading, productivity, and critical results management goals. ... ) , , The Hospital of ...
... , WALTHAM, Mass., Aug. 3 ... advisory firms for pharmaceutical and healthcare issues, finds that, from ... cause a decline of more than eight percent in the ... tract symptoms in the United States, France, Germany, Italy, Spain, ...
Cached Medicine News:Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Blood Type May Boost Pancreatic Cancer Risk 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2Health News:The Hospital of Central Connecticut Chooses AMICAS 2Health News:The Hospital of Central Connecticut Chooses AMICAS 3Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 2Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 3
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , ... SRNE ;  Sorrento), an oncology company ... and Conkwest, Inc., a privately-held immuno-oncology company developing ... (NK) cell-line based therapy, announced today that the ... jointly develop next generation CAR-TNK™ (pronounced as "Car-Tank") ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  Sage ... new generation of equipment for the testing of ... release of the new Luminary™ Profiler, the industry,s ... light-based measurement in a cost-effective, portable unit. ... the specific needs of the cannabis industry, the ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... , WOODCLIFF LAKE, N.J., Nov. 16 Eisai Inc. ... available for use by persons trained in the administration ... intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ... The U.S. Food and Drug Administration (FDA) approved LUSEDRA ...
... , LOS ANGELES, Nov. 16 Cardo Medical, ... company based in Beverly Hills, California, announced today that ... in which it successfully raised approximately $6.2 million in ... , Cardo Medical, Inc. intends to use the proceeds ...
Cached Medicine Technology:LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 2LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 3Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 2Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
Medicine Products: